Copyright Reports & Markets. All rights reserved.

Global and Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Vitamin E & Pioglitazone
    • 1.2.3 Obeticholic Acid (OCA)
    • 1.2.4 Elafibranor
    • 1.2.5 Selonsertib & Cenicriviroc
  • 1.3 Market by Application
    • 1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital Pharmacy
    • 1.3.3 Online Provider
    • 1.3.4 Retail Pharmacy
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2015-2026)
  • 2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions
    • 2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Market Size
    • 3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2015-2020)
  • 3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue
  • 3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio
    • 3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019
  • 3.5 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Area Served
  • 3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
  • 3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type (2015-2026)

  • 4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2021-2026)

5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application (2015-2026)

  • 5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2015-2020)
  • 5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
  • 6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
  • 6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
  • 6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
  • 7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
  • 7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
  • 7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
  • 8.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
  • 8.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
  • 8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
  • 9.2 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
  • 9.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
  • 9.4 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026)
  • 10.2 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Company Details
    • 11.1.2 AstraZeneca Business Overview
    • 11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020))
    • 11.1.5 AstraZeneca Recent Development
  • 11.2 Conatus Pharmaceuticals
    • 11.2.1 Conatus Pharmaceuticals Company Details
    • 11.2.2 Conatus Pharmaceuticals Business Overview
    • 11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.2.5 Conatus Pharmaceuticals Recent Development
  • 11.3 Enzo Biochem
    • 11.3.1 Enzo Biochem Company Details
    • 11.3.2 Enzo Biochem Business Overview
    • 11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.3.5 Enzo Biochem Recent Development
  • 11.4 Galmed Pharmaceuticals
    • 11.4.1 Galmed Pharmaceuticals Company Details
    • 11.4.2 Galmed Pharmaceuticals Business Overview
    • 11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.4.5 Galmed Pharmaceuticals Recent Development
  • 11.5 Genfit
    • 11.5.1 Genfit Company Details
    • 11.5.2 Genfit Business Overview
    • 11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.5.5 Genfit Recent Development
  • 11.6 Gilead
    • 11.6.1 Gilead Company Details
    • 11.6.2 Gilead Business Overview
    • 11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.6.5 Gilead Recent Development
  • 11.7 Horizon Pharma
    • 11.7.1 Horizon Pharma Company Details
    • 11.7.2 Horizon Pharma Business Overview
    • 11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.7.5 Horizon Pharma Recent Development
  • 11.8 Immuron
    • 11.8.1 Immuron Company Details
    • 11.8.2 Immuron Business Overview
    • 11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.8.5 Immuron Recent Development
  • 11.9 Intercept Pharmaceuticals
    • 11.9.1 Intercept Pharmaceuticals Company Details
    • 11.9.2 Intercept Pharmaceuticals Business Overview
    • 11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.9.5 Intercept Pharmaceuticals Recent Development
  • 11.10 Novo Nordisk
    • 11.10.1 Novo Nordisk Company Details
    • 11.10.2 Novo Nordisk Business Overview
    • 11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
    • 11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)
    • 11.10.5 Novo Nordisk Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Non-Alcoholic Steatohepatitis (NASH) Drugs Scope and Market Size
    Non-Alcoholic Steatohepatitis (NASH) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Vitamin E & Pioglitazone
    Obeticholic Acid (OCA)
    Elafibranor
    Selonsertib & Cenicriviroc

    Market segment by Application, split into
    Hospital Pharmacy
    Online Provider
    Retail Pharmacy

    Based on regional and country-level analysis, the Non-Alcoholic Steatohepatitis (NASH) Drugs market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    AstraZeneca
    Conatus Pharmaceuticals
    Enzo Biochem
    Galmed Pharmaceuticals
    Genfit
    Gilead
    Horizon Pharma
    Immuron
    Intercept Pharmaceuticals
    Novo Nordisk

    Buy now